^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20 inhibitor

    Related drugs:
    1d
    Unusual Nasopharyngeal Localization of Chronic Lymphocytic Leukemia: A Case Report. (PubMed, Cureus)
    The patient was treated with six cycles of rituximab-bendamustine, resulting in complete regression of the nasopharyngeal mass and reduction in splenomegaly, with minimal residual lymphadenopathy and good clinical and biological tolerance. This case highlights the importance of considering CLL in the differential diagnosis of nasopharyngeal masses and emphasizes the role of combined imaging, histology, and immunophenotyping in establishing an accurate diagnosis and guiding appropriate management.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    Rituxan (rituximab) • bendamustine
    2d
    TG1101-RMS-SC201: A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability via Autoinjector Device versus Syringe in Patients with Multiple Sclerosis (2025-523757-33-00)
    P1/2, N=120, Not yet recruiting, Tg Therapeutics Inc.
    New P1/2 trial
    |
    Briumvi (ublituximab-xiiy)
    4d
    A051901: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma (clinicaltrials.gov)
    P1, N=47, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • lenalidomide • methotrexate • Truxima (rituximab-abbs) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • methotrexate IV
    4d
    A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov)
    P3, N=360, Recruiting, TG Therapeutics, Inc.
    Trial initiation date • Head-to-Head
    |
    Briumvi (ublituximab-xiiy)
    4d
    Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov)
    P2/3, N=240, Not yet recruiting, TG Therapeutics, Inc. | N=48 --> 240
    Enrollment change • Trial initiation date
    |
    Briumvi (ublituximab-xiiy) • fingolimod
    4d
    SATELITE: Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis (clinicaltrials.gov)
    P3, N=42, Recruiting, Assistance Publique - Hôpitaux de Paris | Suspended --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • Actemra IV (tocilizumab) • tofacitinib
    5d
    Immunoglobulin G4-Related Disease Manifesting as Posterior Uveitis. (PubMed, J Vitreoretin Dis)
    The patient responded well to prednisone and rituximab. IgG4-related disease may present with atypical posterior uveitis findings and mimic intraocular lymphoma. This entity should be considered in the differential diagnosis of posterior uveitis masquerade syndromes.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Rituxan (rituximab) • prednisone
    5d
    Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=50 --> 23
    Enrollment closed • Enrollment change
    |
    EZH2 mutation
    |
    Tazverik (tazemetostat) • Lunsumio (mosunetuzumab-axgb)
    6d
    Prognostic Role of Absolute Monocyte Count, CD163⁺ Macrophages, and CD8⁺ Lymphocytes in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. (PubMed, F1000Res)
    AMC and CD163 are negative prognostic markers, while CD8 is protective. AMC may reflect the immune profile of the TME and serve as a practical prognostic biomarker in DLBCL.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule)
    |
    Rituxan (rituximab)
    6d
    ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, KeshuZhou
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • lenalidomide • Brukinsa (zanubrutinib)
    6d
    CLLRT2: A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation (2024-513445-37-00)
    P2/3, N=57, Not yet recruiting, University Of Cologne
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    6d
    Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov)
    P2/3, N=48, Not yet recruiting, TG Therapeutics, Inc.
    New P2/3 trial
    |
    Briumvi (ublituximab-xiiy) • fingolimod